Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical atorvastatin for dry eye associated with meibomian gland dysfunction
IRCT20250513065716N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in meibomian gland dysfunction (MGD) and dry eye syndrome (DED) comparing Atorvastatin plus standard MGD treatment with Placebo plus standard MGD treatment (2 arms). Primary endpoint: OSDI Questionnaire score. Started Sep 2025; status: completed.
02
Drugs
atorvastatin
03
Conditions
meibomian gland dysfunction (MGD)dry eye syndrome (DED)
Beyond the preview
Go deeper on IRCT20250513065716N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250513065716N1.